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Introduction
Fibroblast growth factor-23 (FGF23) is a major
regulator of phosphate and vitamin D metabolism
often elevated in genetic hypophosphataemic
disorders and in chronic kidney disease. In the
kidney, FGF23 induces urinary phosphate excretion
and reduces synthesis of 1,25-dihydroxyvitamin D
(1,25(OH)2D) by down regulating 1a-hydroxylase
and upregulating 24-hydroxylase activity. We1 and
others2,3 showed a relationship between FGF23 and
various markers of iron status including ferritin, low
serum iron being associated with elevated c-
terminal (cFGF23) but not intact (iFGF23) FGF23
suggesting a role of iron status in the metabolism of
FGF23. Moreover in dyalised patients with chronic
kidney disease (CDK), iron administration lowers
iFGF23 levels4.
Methods
 Samples
Samples with a range of concentrations of cFGF23 (15-6830 RU/mL) were collected in the course
of routine care. Samples were anonymised to the researchers at point of access in accordance
with generic ethical approval.
 Assays
- c-terminal FGF23 (cat# 60-6100) and intact FGF23 (cat# 60-6600) were both two-site enzyme-
linked immunosorbent assay (ELISA) 2nd generation from Immunotopics Inc., CA
- c-terminal FGF23 (cat# BI-20702) was a sandwich enzyme immunoassay from Biomedica.
- intact FGF23 (cat# TCY4000E) was a two-site ELISA from Kainos.
- ferritin (cat# 03737551), urea (cat# 04460715) and creatinine (cat# 04810716) were
immunoassay or kinetic colorimetric assays by Roche Diagnostics (Burgess Hill, UK) measured on
a COBAS 6000
- 25 hydroxyvitamin D (25(OH)D2 and 25(OH)D3) and it’s metabolite 24,25 dihydroxyvitamin D3
(24,25(OH)2D3) were measured by LC-MS/MS (see poster LB-MO0026 for methodology).
 Statistics
- Assay results were compared using Passing Bablock and Bland-Altman analyses.
- Concentrations were compared using one-way ANOVA. Trends were estimated using linear
regression analysis
- SPSS for windows version 22.0.0.1 was used and results were considered statistically significant
for p<0.05 [*p<0.05; ** p<0.01; ***p<0.001].
Objectives:
• Compare the new Biomedica with the routinely used Immunotopics assay for cFGF23.
• Compare concentrations of iFGF23 with cFGF23 in patients with elevated cFGF23.
• Determine ferritin status in patients with elevated cFGF23.
from Prié and Friedlander CJASN 20105
FGF23 assay comparisons
Passing-Bablock between the different cFGF23 and iFGF23 assays
Line represents the best fit; dotted lines represent 95% confidence interval 
 The assay currently in routine use to assess FGF23
status is the cFGF23 assay from Immunotopics.
We compared results from a newly available kit
from Biomedica which showed good correlation
(n = 125 r = 0.966 p<0.01) however, a bias
became apparent in the highest range of FGF23
as shown on the Bland-Altman plot.
 The Intact assay for FGF23 is not in routine use but
requests are increasing. We tested kits from Kainos
and Immunotopics. Both report values in pg/mL and
the results correlated (n = 48 r = 0.963 p<0.01).
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 Two populations could be defined in which
Group 1) iFGF-23 concentrations correlated with
concentrations of cFGF23 (Immunotopics) for both the
Immunotopics (n=43 r=0.959 p<0.01) and Kainos kit
(n=43 r=0.959 p<0.01) and
Group 2) cFGF23 concentrations were elevated without
an elevation of iFGF23.
 [Ferritin] between the two population were
Group 1 ) [ferritin] = 96 ± 18 µg/L
Group 2) [ferritin] = 63 ± 15 µg/L
Difference was not significant.
Conclusions
Vitamin D and FGF23
 3 groups of patients could be isolated
depending on their ferritin status
- Group 1: [ferritin] = 202 ± 47 µg/mL
- Group 2: [ferritin] = 115 ± 9 µg/mL
- Group 3: [ferritin] = 66 ± 11 µg/mL
 The lower the ferritin, the lower the
creatinine and the urea (and
[urea]:[creatinine] ratio).
 Group 2 and 3 had higher [cFGF23],
although not significant.
 In the circulation, vitamin D is present in
two forms; predominantly D3 and to a
lesser extent D2. Overall, no significant
difference in 25(OH)D (total or D3) were
observed.
 However, while group 2 had a
significantly lower 25(OH)D2; group 3 had
a significantly higher 25(OH)D2.
 The concentration of [24,25(OH)2D3]
metabolites was significantly higher in
both group 2 and 3 than group 1.
 The ratio [25(OH)D]:[24,25(OH)2D3] was
significantly lower in both group 2 and 3
than group 1.
 These populations could be 
discriminated by plotting [25(OH)D2] 
against [25(OH)D]:[24,25(OH)2D3] and 
linear regression analysis showed group 
3 was also the only linear population 
with r2 of 0.918 (p<0.001).0
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 Both Biomedica and Immunotopics assays measure cFGF23 and iFGF23. Biomedica allows calculation of cFGF23 in pg/mL (immunotopics is RU/mL), allowing deduction of actual c-FGF23
concentrations.
 Intact FGF23 correlated to c-terminal FGF23 in most cases. However a subpopulation of patients presented with high FGF23 c-terminal without elevation of intact FGF23. This suggest that these
patients metabolise FGF23 differently and are not able to clear FGF23 fragments which accumulate over time.
 We observed in patients with relatively low ferritin higher levels of cFGF23 which is in accordance with previous studies in FGF23 related diseases. Iron deficiency has been shown to be associated
with stimulation of FGF23 transcription and increased concentrations of cFGF23 and iFGF23 in patients with dominant hypophosphatemic rickets while iFGF23 are maintained in controls2.
 Patients with high ferritin/creatinine showed decreased production of vitamin D metabolites which is in accordance with a decrease in hydroxylase activity and lower 1,25(OH)D upon renal failure.
 Iron and FGF23 may act in concert to regulate vitamin D status, more studies are needed to make conclusions on the diagnostic value of these results. Iron and/vitamin D supplementation might
decrease or increase the observed effects.
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